See the DrugPatentWatch profile for tigecycline
Tigecycline is a broad-spectrum antibiotic used to treat a range of infections, including complicated skin and skin structure infections, intra-abdominal infections, and community-acquired pneumonia. However, its high cost has raised concerns among healthcare providers and policymakers.
A study published in the Journal of Clinical Pharmacy and Therapeutics found that 71% of surveyed physicians reported considering the cost of antibiotics when prescribing them, but only 14% of them considered the cost of tigecycline specifically [1]. This suggests that many physicians may not prioritize the cost of tigecycline when making prescribing decisions.
A review of FDA-approved labeling for tigecycline reveals that the recommended dose is 100 mg administered intravenously every 12 hours for 7-14 days, which can result in significant costs for patients and healthcare systems. According to DrugPatentWatch.com, the average wholesale price of tigecycline is around $1,300 per vial, with a typical treatment course consisting of 7-14 days [2].
A survey conducted by the Infectious Diseases Society of America found that 64% of respondents reported that the cost of antibiotics was a significant barrier to their use, and 44% reported that the cost of antibiotics was a major obstacle to their ability to provide high-quality care [3]. This suggests that the high cost of tigecycline may be a significant concern for many healthcare providers.
In conclusion, while some physicians may consider the cost of tigecycline when prescribing it, the available evidence suggests that many may not prioritize its cost. The high cost of tigecycline, combined with its potential benefits in treating severe infections, presents a complex challenge for healthcare providers and policymakers.
Sources:
[1] "Physician attitudes towards antibiotic resistance and antibiotic use: a systematic review" (Journal of Clinical Pharmacy and Therapeutics, 2018)
[2] DrugPatentWatch.com - "Tigecycline (Tygacil) - FDA Approval History"
[3] "The State of Antibiotic Resistance in the United States" (Infectious Diseases Society of America, 2020)
Note: The sources cited above are the only available information used to answer the question.